GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » EPS without NRI

Laekna (HKSE:02105) EPS without NRI : HK$-0.76 (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Laekna EPS without NRI?

Laekna's earnings per share without non-recurring items for the six months ended in Dec. 2024 was HK$-0.33. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.76.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -2.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Laekna's EPS without NRI or its related term are showing as below:

HKSE:02105' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -2.2   Med: -2.2   Max: -2.2
Current: -2.2

During the past 4 years, Laekna's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -2.20% per year. The lowest was -2.20% per year. And the median was -2.20% per year.

HKSE:02105's 3-Year EPS without NRI Growth Rate is ranked worse than
65.21% of 1233 companies
in the Biotechnology industry
Industry Median: 10.5 vs HKSE:02105: -2.20

Laekna's EPS (Diluted) for the six months ended in Dec. 2024 was HK$-0.33. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.76.

Laekna's EPS (Basic) for the six months ended in Dec. 2024 was HK$-0.33. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.76.


Laekna EPS without NRI Historical Data

The historical data trend for Laekna's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laekna EPS without NRI Chart

Laekna Annual Data
Trend Dec21 Dec22 Dec23 Dec24
EPS without NRI
-0.71 -1.14 -1.49 -0.76

Laekna Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EPS without NRI Get a 7-Day Free Trial -0.66 -1.93 -0.43 -0.43 -0.33

Competitive Comparison of Laekna's EPS without NRI

For the Biotechnology subindustry, Laekna's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laekna's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laekna's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Laekna's PE Ratio without NRI falls into.


;
;

Laekna EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laekna  (HKSE:02105) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Laekna EPS without NRI Related Terms

Thank you for viewing the detailed overview of Laekna's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Laekna Business Description

Traded in Other Exchanges
Address
No. 3-2-467, 5 Xingbin Road (Lin Li Center), Sino-Italy Ningbo Ecological Park, Zhejiang Province, Yuyao, CHN, 201203
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.
Executives
Orbimed Advisors Iii Limited 2102 Investment manager
Orbimed Asia Gp Iii, L.p. 2102 Investment manager
Orbimed Asia Partners Iii, L.p. 2102 Investment manager
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo 2101 Beneficial owner
Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si 2101 Beneficial owner
Laekna Wonderland Limited 2101 Beneficial owner
Lu Chris Xiangyang 2501 Other
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Gp Healthcare Capital, Inc. 2101 Beneficial owner
Liu Zeng 2201 Interest of corporation controlled by you
Ealex Llc 2101 Beneficial owner
Futu Trustee Limited 2301 Trustee

Laekna Headlines

No Headlines